Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NasoVAX Phase 2a Safety and Immunogenicity
NCT03232567Phase 2Completed
- Sponsor
- Altimmune, Inc.
- Start
- Sep 2017
- Primary completion
- Mar 2018
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of nasovax in influenza (4 arms), sponsored by Altimmune, Inc. Primary endpoints: Treatment-Emergent Adverse Events and Treatment-Emergent Reactogenicity Events at 14 days. Started Sep 2017; status: completed.
02
Drugs
nasovax
03
Conditions
influenza
Beyond the preview
Go deeper on NCT03232567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03232567.